MedTrace Logo

Olaparib With Ceralasertib in Recurrent Osteosarcoma

NCT04417062 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2026-02-25

No results posted yet for this study

Summary

This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment

The names of the study drugs involved in this study are:

* Olaparib
* Ceralasertib

Conditions

Interventions

DRUG

Olaparib

Olaparib is taken by mouth, twice daily through out the 28 day study cycle.

DRUG

Ceralasertib

Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.

Sponsors & Collaborators

Principal Investigators

  • Katherine Janeway, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-24
Primary Completion
2025-06-01
Completion
2026-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04417062 on ClinicalTrials.gov